Onward Signs a Worldwide Exclusive License and Co-Development Agreement with Biomunex for Immuno-Oncology

Shots:

• Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies
• Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program
• Biomunex is responsible for early preclinical development, while Onward will complete the IND-enabling studies, and will be responsible for GMP manufacture, clinical development, and commercialization

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Onward